Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
Healthcare
$7.21 +6.61%
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
52W Low $0.68High $7.78
Volume 0.61M
Average 0.12M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$3.07M
FY 2025 · Annual
Investing Cash Flow
-$3.17M
FY 2025 · Annual
Financing Cash Flow
$10.31M
FY 2025 · Annual
Cash Flow Statement
USD
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$6.0M
+ D&A$0
+ Stock-Based Comp$1.6M
+ Deferred Tax$0
+ Working Capital$412.9K
+ Other Non-Cash$966.1K
= Operating Cash Flow-$3.1M
- Capex$0
= Free Cash Flow-$3.1M
Analysis
FY2025 free cash flow is -$3.1M. FCF conversion is 51.1% of net income. Operating cash flow was -$3.1M, with capex of $0. The largest bridge item is Stock-Based Comp at $1.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 3 | Initial statement of beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 |
Does LIXT generate free cash flow?
Lixte Biotechnology Holdings, Inc. (LIXT) generated -$3.07M of free cash flow in fiscal 2025.
How much operating cash flow does LIXT produce?
Operating cash flow was -$3.07M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.